What are the potential challenges and opportunities in the future of adult vaccination?

We are excited to announce the publication of a pivotal perspective article, "Exploring the future adult vaccine landscape—crowded schedules and new dynamics," in npj Vaccines. This publication represents a significant milestone in our ongoing collaboration with Pfizer, showcasing the culmination of extensive research and thought leadership in the burgeoning field of adult vaccination.

Read the full article here: https://www.nature.com/articles/s41541-024-00809-z

Why Look Into The Adult Vaccine Market?

The COVID-19 pandemic has undeniably accelerated vaccine innovation, spotlighting the critical role vaccines play not just in pediatric healthcare but across all age groups, including adults and the immunocompromised. Yet, even before the pandemic, the adult vaccine landscape was on the brink of a revolutionary transformation, driven by scientific and technological advancements.

This article, authored by Charles H. Jones, Matthew P. Jenkins, B. Adam Williams, Verna L. Welch, and Jane M. True, delves deep into the complexities and dynamics of the rapidly expanding global market for adult vaccines. With projections indicating over 100 novel, risk-adjusted product launches over the next decade, the adult vaccine sector is set to face both unprecedented opportunities and challenges. Unfortunately, stakeholder interviews unveiled that many are completely unaware of this evolution and burden it will place on the adult vaccine market.

Assessment of the projected future vaccine volume expansion in the U.S., by vaccine category, compared with current and pre-pandemic levels. Notable recent and anticipated vaccine launches are called out. The box around COVID indicates that this launch has already occurred. A more comprehensive representation of anticipated vaccine launches can be found in Supplementary Fig. 1. B Weekly COVID-19 Vaccine Administrations and Productivity in 2022 and Projections for 2032. This figure presents the number of COVID-19 vaccine doses administered weekly throughout 2022. This data was obtained from the CDC’s COVID Data Tracker. Weekly productivity, represented as millions of doses administered per week, during the peak vaccination season (September to December) for actual 2022 COVID-19 vaccine administrations and 2018 influenza administration is shown. Data for influenza vaccines was obtained from the CDC’s FluVaxView. Comparative data is shown for the total vaccine administration volume in 2022 and projections for total vaccine administration volume in 2032, under an assumed forced seasonality and current vaccination behavior.

Key Insights from the Article

The perspective shared in the article is clear: the future of adult vaccination is not merely about innovation in vaccine development. It also requires a holistic approach to addressing low uptake rates, funding shortfalls, and the logistical hurdles that have historically plagued this segment of healthcare. Through detailed analysis and insights from external stakeholder interviews, the article offers a fresh perspective on overcoming these barriers, paving the way for a future where the full societal benefits of adult vaccination can be realized.

Bulmore's Role and Contribution

At Bulmore, we pride ourselves on our ability to provide expert editorial and thought leadership support, a commitment that was fully brought to bear on this project. Our collaboration with Pfizer and the esteemed authors facilitated a comprehensive analysis of the potential impact of these new vaccines, addressing critical factors such as societal and economic benefits, barriers to vaccine uptake among adults, and the operational challenges associated with delivery and administration.

Looking Forward

This publication serves as a crucial starting point for industry participants, equipping them with the knowledge and insights needed to navigate the complexities of the adult vaccine market. It underscores the importance of innovative communication strategies in advancing healthcare and highlights Bulmore's dedication to supporting our partners in achieving their strategic goals.

As we look to the future, Bulmore remains committed to fostering innovation and excellence in healthcare communication. We are excited about the opportunities this article presents for further dialogue and collaboration within the pharmaceutical and healthcare industries.

We invite you to read the full article in npj Vaccines and join us in exploring the dynamic future of adult vaccination.